Comparison of the nephrotoxicity of vancomycin monotherapy and combined with piperacillin tazobactam in pediatric inpatients

Comparison of efficacy and adverse reactions of vancomycin monotherapy and combined with piperacillin tazobactam

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-15006125

Enrollment

Unknown

Registered

2015-03-19

Start date

2015-03-23

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe infections

Interventions

1:vancomycin monothepy

2:piperacillin tazobactam combination of vancomycin

Eligibility

Sex/Gender

All

Age

No minimum to 10 Years

Inclusion criteria

Inclusion criteria: The inpatients aged 0-10,of which the treatment is vancomycin monotherapy or combined with piperacillin tazobactam

Exclusion criteria

Exclusion criteria: Serious liver and kidney dysfunction

Design outcomes

Primary

Measure	Time frame
nephrotoxicity;	—

Countries

China

Contacts

Public ContactLi Zhiping

zhipinglifudan@yeah.net+86 021 64932030

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026